Colorado Medicaid’s Decision to Cover the Nerivio® REN Wearable Expands Access for Nearly Two Million Americans to Drug-Free, Dual Use Migraine Treatment
Theranica, a neuromodulation therapeutics company, today announced Health First Colorado – Colorado Medicaid‘s coverage of the Nerivio® REN wearable, the FDA-cleared, non-drug, non-disruptive treatment for both acute attacks and prevention of migraine with or without aura in adolescents and adults ages 12…
Researchers at Fermata to Study SAINT Neuromodulation for Treatment-Resistant Major Depression
Fermata, an outpatient psychiatric center of excellence, today announced a new clinical trial to study the SAINT™ Neuromodulation System for treating major depressive disorder (MDD) as part of a larger multi-site trial to further develop a more rapid, personalized treatment…
